NextPlat (NASDAQ: NXPL, NXPLW) has secured vendor approval from JD.com, China’s largest self-operated e-Commerce retailer, to sell OPKO Health Europe’s branded health, wellness, and veterinary products. Under an exclusive agreement with OPKO Health Europe, NextPlat will begin listing nutraceutical products for bone and joint health, nutrition, and immunity on JD.com in early 2025, with plans to expand offerings to include innovative veterinary care products pending regulatory clearance. Leveraging JD.com’s platform, which serves over 560 million annual users, this initiative aligns with the growing demand for premium healthcare products in China, where the nutraceutical market is projected to reach $100 billion by 2025. NextPlat’s President, David Phipps, highlighted this development as a significant step in expanding the company’s e-Commerce footprint and driving product sales in China.
To view the full press release, visit: https://ibn.fm/2dmUw
About NextPlat Corp
NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.
NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
